Market Outlook Immune checkpoint inhibitors are revolutionizing the treatment algorithm for unresectable locally advanced or metastatic bladder cancer. Following the 2016/7 FDA approvals of five…
Market Outlook: Hepatocellular carcinoma (HCC) is a primary malignancy of the liver, with the majority of cases arising from underlying liver cirrhosis. Treatment of HCC incorporates a variety of…
Market Outlook Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the main treatment for prostate cancer and are routinely used throughout the course…
Because no current therapy for type 2 diabetes offers disease-modifying capabilities, a high unmet need exists for drugs that can effectively control the progression of this prevalent disease…
DRG Epidemiology's coverage of cholangiocarcinoma comprises epidemiological estimates of key patient populations across the emerging pharmaceutical markets (Brazil, China, India, Mexico, Russia…
DRG Epidemiology's coverage of soft tissue sarcoma comprises epidemiological estimates of key patient populations in the Asia pacific pharmaceutical markets (Australia, Hong Kong, Indonesia,…
The treatment journey for multiple sclerosis (MS) patients in Europe is complicated and individualized, driven by the availability of a broad array of disease-modifying therapies (DMTs)—…
Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells. Over the last few years, a number of agents have been launched that have improved treatment outcomes for patients with ALL,…
MARKET OUTLOOK The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The anticipated entry of first-in-UC oral therapies for the moderate to severe population,…
Sjögren’s syndrome (SS) is a progressive autoimmune disease characterized by chronic inflammation and lymphocytic infiltration of the exocrine glands that may occur alone (primary SS) or with a…
Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative market for pharmacotherapies owing to the lack of approved agents and the prevalence of the disease. The body of…
Market Outlook: Squamous cell carcinoma of the head and neck (SCCHN) is an anatomically and biologically heterogeneous disease that has historically proven to be a complex challenge for drug…
The high number of premium-priced NSCLC therapies and the large number of NSCLC patients result in significant financial burden for payers. These costs are set to increase with the approval of…
Heart failure (HF) can be categorized into acute or chronic, and we focus on both settings in this report. HF patients are subject to high rates of mortality and morbidity. While much progress…
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically, AML treatment has been dominated by…